Chargement en cours...

New and emerging concepts in the use of denosumab for the treatment of osteoporosis

Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine expressed by cells of the osteoblast lineage that is a key regulator of osteoclastic bone resorption. By binding and neutralizing RANKL, denosumab inhibits osteoclast differentia...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ther Adv Musculoskelet Dis
Auteur principal: Lewiecki, E. Michael
Format: Artigo
Langue:Inglês
Publié: SAGE Publications 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204627/
https://ncbi.nlm.nih.gov/pubmed/30386439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X18805759
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!